Condition
EBV Positive Plasma Cell Neoplasm
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Injection Of Ebv Specific Ctls
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Injection Of Ebv Specific Ctls1
Active Sponsors
- Center for Cell and Gene Therapy, Baylor College of Medicine1
- The Methodist Hospital Research Institute1
- Baylor College of Medicine1
Top Investigators
Baylor College of Medicine
Related Conditions
- Epsteinbarr Virusrelated Hodgkin Lymphoma1
- Epsteinbarr Virusrelated Nonhodgkin Lymphoma1